Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.
IPO Year:
Exchange: NASDAQ
Website: sppirx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/26/2023 | Mkt Outperform → Mkt Perform | JMP Securities |
15-12G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
EFFECT - SPECTRUM PHARMACEUTICALS INC (0000831547) (Filer)
JMP Securities downgraded Spectrum Pharma from Mkt Outperform to Mkt Perform
Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum's Board of Directors and as Chairperson of the Audit Committee since December 2020, and will relinquish her Board duties to assume this new role. "We are thrilled to have Ms. Brennan join Spectrum's senior leadership team as we progress our two late-stage assets toward commercialization," stated Tom Riga, CEO of Spectrum Pharmaceuticals. "Nora has been a strong board member and her experience as the audit committee chair will serve her well i
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate development experience. "It's my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum's evolution," stated William Ashton, Chairman of the Board of Spectrum Pharmaceuticals. "As a seasoned executive in M&A and the life sciences sector, Brittany's experience and leadership will make an immediate impact on our board." "I am looking forward to joining Spectrum's Board at a
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors. "We are delighted to have Ms. Lim join Spectrum's Board of Directors," said William Ashton, Chairman of the Board, Spectrum Pharmaceuticals. "This further strengthens our partnership with Hanmi and we look forward to her thoughtful guidance as we strategically define the next chapter at Spectrum and strive to advance novel medicines toward registration and commercialization." Juhyun Lim is an experienced executive with 20 years of experience in the life science industry and currently serves as Preside
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
4 - SPECTRUM PHARMACEUTICALS INC (0000831547) (Issuer)
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres
-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web
-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2022 and provided a corporate update. Third Quarter 2022 and Recent Business Update Launched ROLVEDON™ (eflapegrastim-xnst) injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant inci
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022, at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, November 10, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the
Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2022 and provided a corporate update. "The completion of the FDA re-inspection of the drug substance facility for eflapegrastim is a critical step in the regulatory review process. With
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Thursday, August 11, 2022 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the call will
Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update. "We anticipate FDA approvals later this year fo
Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, May 12, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific Domestic: (877) 837-3910 International: (973) 796-5077 Conference ID#: 2863606 The conference call will also be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations and will be archived there shortly after the live eve
Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2021. "We have made significant progress against our core business objectives including the
Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology. Assertio intends to provide updated guidance for the combined business
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc. ("Spectrum") (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and
Recommendations from the Nation's Leading Independent Proxy Advisory Firms Recognize Value Creation Opportunity for Spectrum Stockholders and Strength of the Combined Company Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") announced today that the leading independent proxy advisory firms, Institutional Shareholder Services, Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have each recommended that Spectrum stockholders vote "FOR" the proposal to adopt the Agreement and Plan of Merger ("Merger Agreement", and such proposal, the "Merger Proposal") at the upcoming special meeting of stockholders (the "Special Meeting") on July 27, 2023. Under the terms of the M
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company"), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company previously received notification from the Staff on November 1, 2022, that its common stock failed to maintain a minimum bid price of $1.00 or more over the previous 30 consecutive business days, as required by the Nasdaq Listing Rules. Since t
-- Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 -- -- Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and contingent value rights (CVR) transaction -- -- Transaction expected to close in Q3 2023 -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update. First Quarter 2023 and Recent Business Update Net sales for Q1 2023 totaled $15.6 million, an increase of 54% compared to Q4 2022. 172 targeted acco
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres
-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023. "This is an important milestone in the ROLVEDON launch. A permanent J-code will enable a more efficient and predictable reimbursement in the outpatient setting. The combination of a permanent J-code on April 1, 2023 and ROLVEDON'S inclusion in the National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) announced on December 6, 2022 are key elements in estab
-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million -- -- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology, today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022. Business Highlights and Preliminary, Unaudited Financial Results Preliminary unaudited net sales for the quarter ending December 31, 2022 are expected to be approximately $10 million ROLVEDON was launched in the U.S. on October 18,
SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13D - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13G - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
SC 13G/A - SPECTRUM PHARMACEUTICALS INC (0000831547) (Subject)
Gainers Airspan Networks Holdings Inc. (NYSE:MIMO) shares rose 50.5% to $0.20 in pre-market trading after dropping 5% on Wednesday. Baosheng Media Group Holdings Limited (NASDAQ:BAOS) shares surged 44% to $8.25 in pre-market trading. Semtech Corporation (NASDAQ:SMTC) gained 24.8% to $28.00 in pre-market trading after the company reported better-than-expected first-quarter results. Acorda Therapeutics, Inc. (NASDAQ:ACOR) gained 18.5% to $13.79 in pre-market trading after adding 14% on Wednesday. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares climbed 17.2% to $21.41 in pre-market trading after the company announced interim clinical data from its 4D-710 Phase 1/2 AEROW clinical tr
HC Wainwright & Co. analyst Edward White reiterates Spectrum Pharma (NASDAQ:SPPI) from Neutral to Neutral.
Jefferies analyst Maury Raycroft downgrades Spectrum Pharma (NASDAQ:SPPI) from Buy to Hold and lowers the price target from $3.5 to $1.5.
Spectrum Pharma (NASDAQ:SPPI) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Spectrum Pharma beat estimated earnings by 66.67%, reporting an EPS of $-0.02 versus an estimate of $-0.06. Revenue was up $15.62 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.05 which was followed by a 2.38% drop in the share price the next day. To track all earnings releases for Spectrum Pharma visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $15.62 million which beat the analyst consensus estimate of $10.50 million by 48.71 percent.
Analysts have provided the following ratings for Spectrum Pharma (NASDAQ:SPPI) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 0 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 2 1 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Spectrum Pharma has an average price target of $3.19 with a high of $4.00 and a low of $0.75. Below is a summary of how these 4 analysts rated Spectrum Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analys
Upgrades Piper Sandler upgraded the previous rating for BankUnited Inc (NYSE:BKU) from Underweight to Neutral. For the first quarter, BankUnited had an EPS of $0.70, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $42.19 and a 52-week-low of $19.04. BankUnited closed at $20.86 at the end of the last trading period. According to Societe Generale, the prior rating for Coca-Cola Europacific Partners PLC (NASDAQ:CCEP) was changed from Sell to Hold. NoneAt the moment, the stock has a 52-week-high of $63.77 and a 52-week-low of $41.81. Coca-Cola Europacific closed at $63.28 at the end of the last trading period. For Microsoft Corp (NASDAQ:MSFT), BMO
HC Wainwright & Co. analyst Edward White downgrades Spectrum Pharma (NASDAQ:SPPI) from Buy to Neutral.
JMP Securities analyst Reni Benjamin downgrades Spectrum Pharma (NASDAQ:SPPI) from Market Outperform to Market Perform.